This case report describes the treatment of an 85-year-old female patient with diffuse large B-cell lymphoma. She received an attenuated version of the R-THP-COP regimen, which includes rituximab, pirarubicin, cyclophosphamide, vincristine, and prednisone. The study followed her for three years to track her progress. During this time, she showed a complete radiological response and was free of reported abdominal symptoms. The treatment was well tolerated, and no adverse events or discontinuations were reported for this single patient.
The main reason to be careful is that this evidence comes from a single case report. Because only one patient was studied, the results cannot be generalized to all elderly patients. The study does not report a primary outcome, and the findings are limited by the small sample size. Readers should understand that this is an early observation that requires confirmation in larger series before it can change standard practice.
For now, this individualized, biopsy-guided, chemotherapy-based approach may be a reasonable option for similarly localised disease in elderly patients. However, doctors should wait for more data before adopting this specific regimen as a standard treatment. The findings suggest potential benefits but highlight the need for further research to ensure safety and effectiveness across a broader group of people.